Premium
Evaluation of 0.6% sodium alginate as a submucosal injection material in endoscopic submucosal dissection for early gastric cancer
Author(s) -
Kusano Toru,
Etoh Tsuyoshi,
Akagi Tomonori,
Ueda Yoshitake,
Shiroshita Hidefumi,
Yasuda Kazuhiro,
Satoh Masahiro,
Inomata Masafumi,
Shiraishi Norio,
Kitano Seigo
Publication year - 2014
Publication title -
digestive endoscopy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.5
H-Index - 56
eISSN - 1443-1661
pISSN - 0915-5635
DOI - 10.1111/den.12268
Subject(s) - medicine , sodium hyaluronate , endoscopic submucosal dissection , sodium carboxymethylcellulose , catheter , sodium alginate , clinical efficacy , hyaluronic acid , adverse effect , gastroenterology , surgery , sodium , anatomy , chemistry , organic chemistry
Background and Aim We have focused on sodium alginate ( SA ) solution as a potential submucosal injection material for endoscopic submucosal dissection ( ESD ). A previous SA solution had high viscosity and problems such as difficult handling. After its properties were adjusted, SA solution was examined in vitro and its clinical safety was evaluated. Methods With 0.4% sodium hyaluronate ( SH ) solution as a control, catheter injectability and mucosa‐elevating capacity of 0.3–0.8% SA solutions were evaluated. Next, 0.6% SA solution was used for ESD in 10 patients with early gastric cancer in a prospective clinical study. Results Compared with 0.4% SH solution, 0.6% SA solution exhibited no significant difference in catheter injectability but significant superiority in mucosa‐elevating capacity. In the clinical study, no adverse events were observed in any patient. Conclusion The safety of 0.6% SA solution as a submucosal injection material was confirmed and it is suggested that its efficacy should be investigated in a larger number of cases.